ICEF 15

Drug Profile

ICEF 15

Alternative Names: aSMDC - Innovacell Biotechnologie GmbH; autologous Skeletal Muscle Derived Cells - Innovacell Biotechnologie GmbH; ICEF-15; NPJ 5007

Latest Information Update: 29 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovacell Biotechnologie GmbH
  • Developer Innovacell Biotechnologie GmbH; Norgine
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Faecal incontinence

Most Recent Events

  • 29 Sep 2015 ICEF 15 is still in phase II trials for Faecal Incontinence (In the elderly, In adults) in Austria, Bulgaria, Germany, Slovenia, Sweden and the United Kingdom
  • 29 Sep 2015 Phase-II clinical trials in Faecal Incontinence (In the elderly, In adults) in Czech Republic (IM)
  • 17 Dec 2013 Innovacell and Norgine agree to co-develop ICEF 15 in Middle East, North Africa, and Southern Africa for Stress incontinence
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top